Clinical outcome and prognostic analysis of meningeal carcinomatosis treated by intrathecal chemotherapy.
OBJECTIVE
To evaluate the clinical efficacy of meningeal carcinomatosis (MC) treated by intrathecal chemotherapy (IC) and analyzes the prognostic factors.


METHODS
The clinical and follow-up data of 33 MC patients was collected and retrospectively analyzed. Potential prognostic factors such as age, gender, primary cancer, transfer time, presence of brain metastasis, intracranial pressure, protein, glucose, vascular endothelial growth factor (VEGF), eastern cooperative oncology group (ECOG) performance status (PS), systemic treatment and IC were discussed.


RESULTS
The most common clinical manifestation of MC was high intracranial pressure (30 cases). The negative rate of cerebrospinal fluid cytology was 50% after MC patients treated by IC. The remission rate of IC and no-IC group was 71.4% and 15.7%, respectively, of which the stability rate was 92.8% and 57.8% with significant difference. The median survival time was 5.200 months (95% CI 0.000-11.491) and the survival rate of 3, 6, 12 months were respectively 71.6%, 49.2%, 30.7%.


CONCLUSION
IC can relieve the symptoms of MC and extend life expectancy. Early treatment can improve prognosis. Presence of brain metastasis, ECOG PS and IC were correlated with prognosis of patients, whereas IC is an independent prognostic factor.
['Meng|Zhaohua|Z|', 'Zhang|Qinqin|Q|', 'Hong|Kun|K|', 'Han|Weixin|W|', 'Zhao|Zeyan|Z|', 'Liu|Yajuan|Y|', 'He|Junying|J|', 'Bu|Hui|H|']
D000328:Adult D000368:Aged D000970:Antineoplastic Agents D001932:Brain Neoplasms D005260:Female D005500:Follow-Up Studies D006801:Humans D007278:Injections, Spinal D019586:Intracranial Hypertension D008297:Male D055756:Meningeal Carcinomatosis D008875:Middle Aged D011379:Prognosis D012189:Retrospective Studies D015996:Survival Rate D016896:Treatment Outcome
prognostic analysis Intrathecal chemotherapy clinical efficacy cerebrospinal fluid cytology meningeal carcinmatosis